The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1420
Ospemifene (Osphena) for Dyspareunia
The full article is available to subscribers Subscriber Login   

The FDA has approved ospemifene (os pem’ i feen; Osphena – Shionogi), an estrogen agonist/antagonist, for oral treatment of moderate to severe dyspareunia in postmenopausal women. Ospemifene is the fourth estrogen agonist/antagonist to be marketed in the US, but it is the only one that has an estrogen-like effect on vaginal epithelium. The other three, tamoxifen (Nolvadex, and generics), toremifene (Fareston), and raloxifene (Evista), are used for treatment and prevention of breast cancer and osteoporosis.

TREATMENT OF DYSPAREUNIA — Vulvovaginal atrophy is common among postmenopausal women and may cause irritation, itching, vaginal dryness and pain with intercourse (dyspareunia). Over-the-counter nonhormonal moisturizers and lubricants (Replens, K-Y, and others) may provide adequate symptom relief for some women, but do not treat the underlying ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ospemifene (Osphena) for Dyspareunia
Article code: 1420c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian